BD Earns EU Nod for Liverty TIPS Stent Graft

BD (Becton, Dickinson and Company) announced CE mark approval for its Liverty TIPS stent graft, bringing portal hypertension care across the European Union.

Liverty was designed to expand treatment options for cirrhosis and complications of portal hypertension. The next-gen, adjustable-diameter device is the latest BD advancement in interventional therapies addressing complex liver disease.

Transjugular intrahepatic portosystemic shunt (TIPS) procedures help reduce symptoms caused by elevated portal pressure in cirrhosis by lowering that pressure and improving blood flow. The Liverty TIPS stent graft was engineered for individualized patient management, with a 6-10mm adjustable inner diameter and the broadest range of covered TIPS stent lengths currently available, BD said.

Features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation with carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system designed for placement accuracy, control, and ease of use.

“For patients living with complications of portal hypertension, access to safe, effective and adaptable treatment options is critical,” said Rima Alameddine, worldwide president of Peripheral Intervention at BD. “With CE Marking of the Liverty TIPS Stent Graft, we’re introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long‑term outcomes.”

BD also announced that data from the ARCH clinical study, a global, prospective, multi‑center, single‑arm clinical study assessing the safety and effectiveness of the Liverty TIPS Stent Graft for the treatment of complications from portal hypertension, will be presented for the first time on podium by Global Principal Investigator Prof. Ziv Haskal, MD, at SIR in April.

“The Liverty TIPS Stent Graft represents an important advancement in how we care for patients with the serious complications of portal hypertension,” said Dr. Haskal. “Its adjustable diameter and delivery design allow physicians to better match the shunt to a patient’s unique physiology, a key consideration in safe and effective TIPS creation. The trial provides the first and only prospective data describing the results of small diameter calibrated TIPS for treating all the major complications of portal hypertension. I look forward to presenting the ARCH study results at SIR.”